ConductScience.org, home

Paper38534720

Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa.

Ferous S and 4 others. Antibiotics (Basel), 2024. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa. Papers, record 38534720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38534720

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa.
PubMed
Journal
Antibiotics (Basel)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
6.22, provisional
iCite
Revised in PubMed
2024-04-26
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ferous SStefanoshttps://orcid.org/0009-0003-4670-5786
2Anastassopoulou CCleohttps://orcid.org/0000-0001-7666-9198
3Pitiriga VVassilikihttps://orcid.org/0000-0002-1951-8489
4Vrioni GGeorgiahttps://orcid.org/0000-0003-4766-8238
5Tsakris AAthanasioshttps://orcid.org/0000-0003-0656-4715

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References122

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124041554Evaluation of Etest® strips for detection of KPC and metallo-carbapenemases in Enterobacteriaceae.Diagn Microbiol Infect Dis2013https://conductscience.org/library/papers/24041554PubMed
236878411In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.Int J Antimicrob Agents2023https://conductscience.org/library/papers/36878411PubMed
331365094Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.J Antimicrob Chemother2019https://conductscience.org/library/papers/31365094PubMed
430649310In vitro synergistic activity of meropenem/vaborbactam in combination with ceftazidime/avibactam against KPC-producing Klebsiella pneumoniae.J Antimicrob Chemother2019https://conductscience.org/library/papers/30649310PubMed
537004964
Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.
Microb Pathog2023https://conductscience.org/library/papers/37004964PubMed
627927915Comparative Evaluation of Four Phenotypic Tests for Detection of Carbapenemase-Producing Gram-Negative Bacteria.J Clin Microbiol2017https://conductscience.org/library/papers/27927915PubMed
722057701β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.Clin Infect Dis2012https://conductscience.org/library/papers/22057701PubMed
822649010Imported Klebsiella pneumoniae carbapenemase-producing K. pneumoniae clones in a Greek hospital: impact of infection control measures for restraining their dissemination.J Clin Microbiol2012https://conductscience.org/library/papers/22649010PubMed
936943617Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series.Infect Dis Ther2023https://conductscience.org/library/papers/36943617PubMed
1028951106In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.Int J Infect Dis2017https://conductscience.org/library/papers/28951106PubMed
1137764003First Detection and Molecular Characterization of Pseudomonas aeruginosa blaNDM-1 ST308 in Greece.Microorganisms2023https://conductscience.org/library/papers/37764003PubMed
1235052925NDM Production as a Dominant Feature in Carbapenem-Resistant Enterobacteriaceae Isolates from a Tertiary Care Hospital.Antibiotics (Basel)2021https://conductscience.org/library/papers/35052925PubMed
1316251324Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase.Antimicrob Agents Chemother2005https://conductscience.org/library/papers/16251324PubMed
1430216371Rapid detection of NDM, KPC and OXA-48 carbapenemases directly from positive blood cultures using a new multiplex immunochromatographic assay.PLoS One2018https://conductscience.org/library/papers/30216371PubMed
1533199392Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/33199392PubMed
169055993Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein.Antimicrob Agents Chemother1997https://conductscience.org/library/papers/9055993PubMed
1730020449Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations.Clin Infect Dis2019https://conductscience.org/library/papers/30020449PubMed
1831863899Resistance to ceftazidime-avibactam and underlying mechanisms.J Glob Antimicrob Resist2020https://conductscience.org/library/papers/31863899PubMed
1934268382Carbapenemase detection by NG-Test CARBA 5-a rapid immunochromatographic assay in carbapenem-resistant Enterobacterales diagnosis.Ann Transl Med2021https://conductscience.org/library/papers/34268382PubMed
2035900090Increased Expression and Amplification of blaKPC-2 Contributes to Resistance to Ceftazidime/Avibactam in a Sequence Type 11 Carbapenem-Resistant Klebsiella pneumoniae Strain.Microbiol Spectr2022https://conductscience.org/library/papers/35900090PubMed

See all 122 referencesDownload CSV of references

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
42938753In Vitro and In Vivo Efficacy of the Broad-Spectrum β-Lactamase Inhibitor APC24-7 in Combination with Meropenem Against Carbapenem-Resistant Enterobacterales.Antibiotics (Basel)2026https://conductscience.org/library/papers/42938753PubMed
42938727Carbapenemases in Gram-Negative Bacilli: Classification, Detection, Therapeutic Options, and Resistance to Novel Antimicrobials.Antibiotics (Basel)2026https://conductscience.org/library/papers/42938727PubMed
42923582Resistance profile and clinical outcomes of Xuebijing injection combined with antibiotics for carbapenem-resistant Pseudomonas aeruginosa infection: a single-center retrospective cohort study.Am J Transl Res2026https://conductscience.org/library/papers/42923582PubMed
42868159Investigation on the use of ceftazidime-avibactam at a national hospital in Vietnam.PLoS One2026https://conductscience.org/library/papers/42868159PubMed
42795452
Carbapenem-Resistant Klebsiella pneumoniae in Healthcare-Associated Infections: Global and Regional Epidemiology, Resistance Mechanisms, and Therapeutic Strategies, with Particular Attention to Romania and Eastern Europe (2020-2025).
Microorganisms2026https://conductscience.org/library/papers/42795452PubMed
42560298Multidrug-Resistant Salmonella and Shigella: Epidemiology, Resistance Mechanisms, and Emerging Therapeutic Strategies.Pol J Microbiol2026https://conductscience.org/library/papers/42560298PubMed
42238879Identification of a novel natural compound inhibitor targeting AmpC β-lactamase to combat multidrug-resistant Pseudomonas aeruginosa.Front Microbiol2026https://conductscience.org/library/papers/42238879PubMed
41897305A High-Affinity Nanobody Selectively Recognizing KPC-2/KPC-3: Biochemical and Structural Insights.Biomolecules2026https://conductscience.org/library/papers/41897305PubMed
41246002bla IMP-45 Amplification Facilitates Heterogeneous Resistance to Imipenem in Pseudomonas aeruginosa.Infect Drug Resist2025https://conductscience.org/library/papers/41246002PubMed
41117673The Achilles' heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing.J Antimicrob Chemother2025https://conductscience.org/library/papers/41117673PubMed
41024947Antimicrobial dosing considerations in critically ill patients with acute kidney injury: A review.World J Nephrol2025https://conductscience.org/library/papers/41024947PubMed
41023351
Detection of colistin resistance from Escherichia colicolonies grown on agar cultures and bacterial pellets obtained from positively flagged blood cultures by MALDI-TOF MS-based rapid assay: aproof-of-concept study.
Eur J Clin Microbiol Infect Dis2025https://conductscience.org/library/papers/41023351PubMed
41009877Epidemiological Trends of Carbapenemase-Producing Pseudomonas aeruginosa in a Tertiary Care Hospital in Athens, Greece, During 2020-2023.Antibiotics (Basel)2025https://conductscience.org/library/papers/41009877PubMed
41001706Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales.J Antimicrob Chemother2025https://conductscience.org/library/papers/41001706PubMed
40827922Establishing the reference broth microdilution MIC method for cefepime-taniborbactam.J Clin Microbiol2025https://conductscience.org/library/papers/40827922PubMed
40761277Global prevalence and antibiotic resistance profiles of carbapenem-resistant Pseudomonas aeruginosa reported from 2014 to 2024: a systematic review and meta-analysis.Front Microbiol2025https://conductscience.org/library/papers/40761277PubMed
40558206Oxacillin-Supplemented Mueller-Hinton Agar for In Vitro Inhibition of Ambler Class C β-Lactamases in Enterobacterales.Antibiotics (Basel)2025https://conductscience.org/library/papers/40558206PubMed
40558176Challenges of Carbapenem-Resistant Enterobacteriaceae in the Development of New β-Lactamase Inhibitors and Antibiotics.Antibiotics (Basel)2025https://conductscience.org/library/papers/40558176PubMed
40422861Comprehensive analysis of extensive drug-resistant Salmonella Typhi in Gujarat region, India: genomic findings and prospective alternative therapy.Microbiol Spectr2025https://conductscience.org/library/papers/40422861PubMed
40278619Deciphering Multidrug-Resistant Pseudomonas aeruginosa: Mechanistic Insights and Environmental Risks.Toxics2025https://conductscience.org/library/papers/40278619PubMed

See all 25 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38534720

GET https://conductscience.org/api/papers/v1/38534720/references?page=2